Latest Breaking News On - Insider activity at crinetics pharmaceuticals - Page 1 : comparemela.com

Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target Raised to $70.00

Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its price target increased by Morgan Stanley from $50.00 to $70.00 in a research note released on Thursday, Benzinga reports. They currently have an overweight rating on the stock. Other analysts also recently issued research reports about the stock. Robert W. Baird raised their price target on shares […]

United statesStephenf betzRobertw bairdRichard scott struthersJanus henderson groupComerica bankArtal groupAnalyst recommendations for crinetics pharmaceuticalsInsider activity at crinetics pharmaceuticalsSecurities exchange commissionInvestment company incCrinetics pharmaceuticals company profileCrinetics pharmaceuticalsCrinetics pharmaceuticals stock performanceInstitutional trading of crinetics pharmaceuticalsCantor fitzgerald

E Fund Management Co. Ltd. Acquires 2,914 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)

E Fund Management Co. Ltd. Acquires 2,914 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.

Dana pizzutiRichard scott struthersPiper sandlerCrinetics pharmaceuticalsMorgan stanleyJennison associatesQuarter for crinetics pharmaceuticalsVanguard group incCrinetics pharmaceuticals trading downSecurities exchange commissionInsider activity at crinetics pharmaceuticalsCrinetics pharmaceuticals profileE fund management coCrinetics pharmaceuticals incNews ratings for crinetics pharmaceuticals dailyEventide asset management

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of "Moderate Buy" from Analysts

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of "Moderate Buy" from Analysts
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Profund Advisors LLC Increases Stock Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)

Profund Advisors LLC Increases Stock Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Dana pizzutiStephenf betzInvesco ltdJefferies financial groupCantor fitzgeraldCrinetics pharmaceuticals stockJpmorgan chase coCrinetics pharmaceuticals incNorthern trust corpCrinetics pharmaceuticals company profileMorgan stanleyInsider activity at crinetics pharmaceuticalsCrinetics pharmaceuticalsQuarter for crinetics pharmaceuticalsNews ratings for crinetics pharmaceuticals dailyExchange commission

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives $44.90 Average PT from Brokerages

Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the eleven brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and ten have issued a buy recommendation on the company. The average twelve-month target […]

Richard scott struthersStephenf betzHighmark wealth managementCrinetics pharmaceuticals price performanceRoyal bankCrinetics pharmaceuticals incJefferies financial groupInstitutional trading of crinetics pharmaceuticalsChina universal asset management coOsaic holdings incNews ratings for crinetics pharmaceuticals dailyCrinetics pharmaceuticalsAnalyst recommendations for crinetics pharmaceuticalsCantor fitzgeraldCrinetics pharmaceuticals company profileJpmorgan chase co